Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prof-004
- Development stage
- Preclinical
- Lead developer
- ProFem
01
Overview
Prof-004 is an early-stage drug candidate being developed by ProFem, an Austrian biotechnology company specializing in women's health. It is currently in the preclinical or lead candidate stage for the treatment of chronic cystitis (chronic bladder infection). While specific details regarding its molecular structure, modality, and exact mechanism of action have not been publicly disclosed, ProFem's broader technological platform focuses on addressing infectious diseases of the female urogenital tract, particularly by targeting biofilm-associated resistance mechanisms and normalizing microorganism-host interactions.
- Other names
- Prof-004-ProFemProf004-ProFemProf 004-ProFem
Beyond the preview
Go deeper on Prof-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prof-004.